Enzyme FTO Shows Potential as Cancer Treatment Target
Researchers are investigating the FTO enzyme to potentially disrupt tumor growth and treatment resistance in gastrointestinal cancers.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that emerging cancer research leads to meaningful improvements in patient treatment?
A 2026 review highlights the FTO enzyme as a promising therapeutic target for various gastrointestinal cancers. This research explores how manipulating this enzyme could one day influence tumor development and improve treatment outcomes.
Why it matters
The FTO enzyme acts as both an oncogene and a tumor suppressor, meaning therapeutic strategies must be carefully tailored to the specific biological context of a patient's cancer. Identifying this dual role helps researchers refine how they might one day design treatments that limit cancer growth while minimizing off-target effects.
A 2026 review published in Genes & Diseases (Volume 13, Issue 6) synthesizes existing experimental data on FTO as an RNA demethylase. The review characterizes preclinical findings where small-molecule inhibitors, such as Rhein and Dac51, show anticancer potential in laboratory models.
The details
The FTO enzyme functions as an RNA demethylase, removing N6-methyladenosine modifications that otherwise regulate RNA stability, degradation, and translation. By influencing these pathways, the enzyme controls cellular movement and tumor growth. Because FTO also undergoes post-translational modifications like acetylation and phosphorylation, researchers are investigating how to precisely modulate its activity without disrupting healthy cellular processes.
Timeline
2026: The research review was published in Genes & Diseases, Volume 13.
Health Landscape
This research builds on the rapidly evolving field of epitranscriptomics, which investigates how chemical modifications to RNA regulate gene expression. It marks a shift toward targeting the underlying machinery of RNA stability to combat treatment resistance in gastrointestinal cancers.
This research is in the early experimental stages and does not currently change existing cancer treatment protocols or clinical recommendations. Patients concerned about specific gastrointestinal cancer treatments should discuss current standard-of-care options and clinical trial opportunities with their oncologist.
The takeaway
The FTO enzyme is a key regulator of RNA processes that cancer cells often exploit to survive and grow. While new inhibitors are being tested in labs, the primary takeaway is the importance of tracking advancements in molecular oncology as potential future treatment strategies emerge.
Further reading
For more information on current treatment trends, see our Cancer section.
Live Poll
Do you trust that emerging cancer research leads to meaningful improvements in patient treatment?
